I remember back when part of the Adelaide Hospital challenged the ownership of the IP behind the insulin producing skin patch! I believe this was why Pros Greenwood sold his 20% holding in Novoskin back to PNV and why Novoskin has now been incorporated into the Polynovo corporate structure to protect the IP up to that point, PNV then proceeded to set up a partnership with Prof Greenwoods Skin technology, I believe the whole reason why this was done was to protect ownership of PNV IP and also what Prof Greenwood had done up until that point!
It also set up a new partnership between PNV and Prof Greenwood and Prof Coates, but don't be surprised if the Adelaide Hospital and also Beta Cell technologies are part of that partnership as well? there will be plenty to go around in my opinion. and for the same reasons this is why a partnership is being set up with Monash Uni and the Alfred Hospital, there can be no doubt who owns the original IP, when Prof Greenwood sold his 20% holding of Novoskin and immediately after, PNV owned all of the technology developed on CEA technology at that point by Prof Geeenwood and they still do.
Prof Greenwood and his own company now own what he adds to this I believe, but the partnership between all parties will be calculated on who owns what I reckon when it comes time to calculate the spoils?
JEV,I believe this was why NovoSkin was so important to PNV , no other reason IMHO.
When it says below
"the person’s own cells and simultaneous deposition of multiple biological materials,"
I don't believe for one minute they are just talking about the patients own Islet cells?"
This is because the person’s own cells can be used throughout the process. This process allows for simultaneous deposition of multiple biological materials" and this "The PICT Printer will allow us to make customised organs, mixing donor with recipient cells in a unique three dimensional way to provide completely new composite ‘organoids’ for experimental transplantation,”
It is well worth remembering that the SKIN is the largest ORGAN in the body.
And this technology may be used for more than just Insulin production, there are many other examples of Organoids beside that.
Sorry Dman, I reckon this deserves a thread of it's own IMHO, what say ye?
A 3D printer developed to help people with type 1 diabetes could help tackle “big clinical challenges”, researchers say.
The Pancreatic Islet Cell Transplantation (PICT) 3D Printer works by delivering insulin-producing islet cells. It has been developed by an Australian research team, who have gifted it to the Royal Adelaide Hospital (RAH), making it the first hospital in the country to receive such cutting-edge technology.
At the moment, islet cell transplantation from human donors is only carried out on people who have severe health problems from type 1 diabetes, but there is always the risk of cell donor rejection.
To tackle that problem the research team from the ARC Centre of Excellence for Electromaterials Science (ACES), based at the University of Wollongong (UOW), incorporated micro-valve ink jet dropping into the kit, which helps keep the islet cells in place. This is because the person’s own cells can be used throughout the process.
This process allows for simultaneous deposition of multiple biological materials, enabling “customized organs”, according to RAH Director of Kidney and Islet Transplantation, Professor Toby Coates.
“The PICT Printer will allow us to make customised organs, mixing donor with recipient cells in a unique three dimensional way to provide completely new composite ‘organoids’ for experimental transplantation,” said Coates.
ACES Executive Director and ANFF Materials Director Professor Gordon Wallace said: “ACES at the University of Wollongong has built a collaborative clinical research network that enables us to tackle big clinical challenges and deliver practical solutions using 3D bioprinting.
“In collaboration with Professor Toby Coates’ team at Royal Adelaide Hospital, we plan to improve the effectiveness of islet cell transplants by encapsulating donated islet cells in a 3D printed structure, to protect them during and after transplantation.”
Further development is to be carried out on the printer, funded from an Australian Research Council’s Linkage, Infrastructure, Equipment and Facilities (LIEF) grant.
(20min delay)